http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006096426-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33b011e77b33662b8bf1f2ff2de7b661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39537fa233c4740013b49f473244ce96 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-757 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6911 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate | 2006-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8965332a425d7229f02145bd84763de |
| publicationDate | 2007-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2006096426-A3 |
| titleOfInvention | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| abstract | Drug delivery is targeted to new opioid receptors using receptor - mediated internalization. Dermorphin was successfully conjugated to DSPE-PEG3400 without affecting the affinity to its receptor. The synthesized conjugate was inserted into preformed sterically stabilized liposomes to obtain dermorphin-grafted SSL. DSPE- PEG34Qo-dermorphin and dermorphin-SSL retained their affinity and selectivity for MOR. Moreover, dermorphin-SSL and encapsulated probes were taken up by CHO- hMOR cells, but not by naive CHO cells or very closely related CHO-hDOR cells. Dermorphin-SSL can be used to deliver drugs to the intracellular component of intended cells with high fidelity. Therefore, dermorphin-SSL is useful to carry pharmaceutical agents to achieve region-specific delivery of analgesics and/or to attenuate side effects associated with opioids. |
| priorityDate | 2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.